Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-label, Expanded Access Program to Provide 100 mg CT1812 (Zervimesine) and to Collect Long-term Safety and Efficacy Data in Participants With Mild-to-moderate Dementia With Lewy Bodies (DLB).

Next Previous
Trial Profile

A Single-arm, Open-label, Expanded Access Program to Provide 100 mg CT1812 (Zervimesine) and to Collect Long-term Safety and Efficacy Data in Participants With Mild-to-moderate Dementia With Lewy Bodies (DLB).

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zervimesine (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Expanded access; Therapeutic Use
  • Sponsors Cognition Therapeutics

Most Recent Events

  • 21 Nov 2025 Status changed from recruiting to completed.
  • 03 Jun 2025 Status changed from suspended to recruiting, according to a Cognition Therapeutics media release.
  • 03 Jun 2025 According to a Cognition Therapeutics media release, eight U.S. sites, all of which were active in the SHIMMER study, were selected to participate in the EAP.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top